Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Climb Bio presented initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026, with the 200 mg cohort showing B-cell depletion, 70% mean PLA2R antibody reduction at Week 12, and immunologic remission in 5 of 13 patients (38%). Emerging 600 mg data show greater drug exposure and deeper B-cell depletion (98% vs 74% CD20+ suppression at Week 4), and population PK analysis supporting higher doses in proteinuric patients. Budoprutug was generally well tolerated, with no treatment-related serious adverse events. A separate MCD case study described three-year steroid-free remission after budoprutug treatment.
Key figures
- Drug Name
- budoprutug
- Phase Of Trial
- Phase 2
- Doses evaluated
- ["200 mg","600 mg","1000 mg"]
- Next data expected
- 2027
- Bcell suppression week4
- 98% at 600 mg vs 74% at 200 mg
- Immunologic remission rate
- 38% (5 of 13 patients)
- Mean pla2r reduction week12
- 70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.